Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.
The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with non small cell lung cancer who have already received one platinum based chemotherapy.
Non Small Cell Lung Cancer
DRUG: SH T00268C|DRUG: PTK787/ ZK 222584
Tumor response rate (complete or partial response according to RECIST)., At baseline and every 8 weeks afterwards
Time to disease progression., At baseline and every 8 weeks afterwards
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.